{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:19:26Z","timestamp":1793366366532,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81627805"],"award-info":[{"award-number":["81627805"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-024-01060-2","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T05:09:35Z","timestamp":1735880975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A KIF20A-based thermosensitive hydrogel vaccine effectively potentiates immune checkpoint blockade therapy for hepatocellular carcinoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Xingyang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feichao","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihua","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"1060_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1060_CR2","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"New Engl. J. Med."},{"key":"1060_CR3","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1002\/hep.32447","volume":"75","author":"F Foerster","year":"2022","unstructured":"Foerster, F., Gairing, S. J., Ilyas, S. I. & Galle, P. R. Emerging immunotherapy for HCC: a guide for hepatologists. Hepatology 75, 1604\u20131626 (2022).","journal-title":"Hepatology"},{"key":"1060_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang, J. D. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastro. Hepat. 16, 589\u2013604 (2019).","journal-title":"Nat. Rev. Gastro. Hepat."},{"key":"1060_CR5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","volume":"158","author":"Z Brown","year":"2023","unstructured":"Brown, Z. et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 158, 410\u2013420 (2023).","journal-title":"JAMA Surg."},{"key":"1060_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau, T. et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. The lancet oncology 23, 77\u201390 (2022).","journal-title":"The lancet oncology"},{"key":"1060_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13046-021-01968-w","volume":"40","author":"X Luo","year":"2021","unstructured":"Luo, X., Wu, K. & He, X. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. J. Exp. Clin. Cancer Res. 40, 172 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1060_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1001\/jamaoncol.2020.3381","volume":"7","author":"M Pinter","year":"2021","unstructured":"Pinter, M., Jain, R. K. & Duda, D. G. The Current landscape of immune checkpoint blockade in hepatocellular carcinoma: A Review. JAMA Oncol. 7, 113\u2013123 (2021).","journal-title":"JAMA Oncol."},{"key":"1060_CR9","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J. Hepatol. 78, 770\u2013782 (2023).","journal-title":"J. Hepatol."},{"key":"1060_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"Yang, C. et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat. Rev. Gastro. Hepat. 20, 203\u2013222 (2023).","journal-title":"Nat. Rev. Gastro. Hepat."},{"key":"1060_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","volume":"3","author":"MJ Lin","year":"2022","unstructured":"Lin, M. J. et al. Cancer vaccines: the next immunotherapy frontier. Nat. Cancer 3, 911\u2013926 (2022).","journal-title":"Nat. Cancer"},{"key":"1060_CR12","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.trecan.2024.06.003","volume":"10","author":"A Brandenburg","year":"2024","unstructured":"Brandenburg, A., Heine, A. & Brossart, P. Next-generation cancer vaccines and emerging immunotherapy combinations. Trends Cancer 10, 749\u2013769 (2024).","journal-title":"Trends Cancer"},{"key":"1060_CR13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360\u2013378 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1060_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/hep.31279","volume":"73","author":"L Lu","year":"2021","unstructured":"Lu, L. et al. Targeting neoantigens in hepatocellular carcinoma for immunotherapy: a futile strategy? Hepatology 73, 414\u2013421 (2021).","journal-title":"Hepatology"},{"key":"1060_CR15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/hep.31502","volume":"73","author":"L Lu","year":"2021","unstructured":"Lu, L. et al. Targeting tumor\u2010associated antigens in hepatocellular carcinoma for immunotherapy: past iitfalls and future strategies. Hepatology 73, 821\u2013832 (2021).","journal-title":"Hepatology"},{"key":"1060_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu, Z., Ott, P. A. & Wu, C. J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol. 18, 168\u2013182 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"1060_CR17","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","volume":"185","author":"M Sellars","year":"2022","unstructured":"Sellars, M., Wu, C. & Fritsch, E. Cancer vaccines: building a bridge over troubled waters. Cell 185, 2770\u20132788 (2022).","journal-title":"Cell"},{"key":"1060_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","volume":"38","author":"V Leko","year":"2020","unstructured":"Leko, V. & Rosenberg, S. A. Identifying and targeting human tumor antigens for T Cell-based immunotherapy of solid tumors. Cancer Cell 38, 454\u2013472 (2020).","journal-title":"Cancer Cell"},{"key":"1060_CR19","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1158\/0008-5472.CAN-22-0225","volume":"82","author":"B Xie","year":"2022","unstructured":"Xie, B. et al. Proteomic mapping and targeting of mitotic pericentriolar material in tumors bearing centrosome amplification. Cancer Res. 82, 2576\u20132592 (2022).","journal-title":"Cancer Res."},{"key":"1060_CR20","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1016\/j.apsb.2022.05.021","volume":"12","author":"J Wei","year":"2022","unstructured":"Wei, J. et al. Cucurbitacin B-induced G2\/M cell cycle arrest of conjunctival melanoma cells mediated by GRP78\u2013FOXM1\u2013KIF20A pathway. Acta Pharm. Sin. B 12, 3861\u20133876 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"1060_CR21","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1158\/1538-7445.AM2022-1813","volume":"82","author":"Y Collette","year":"2022","unstructured":"Collette, Y. et al. Abstract 1813: DIACC2010, a selective inhibitor of KIF20A. Cancer Res. 82, 1813\u20131813 (2022).","journal-title":"Cancer Res."},{"key":"1060_CR22","doi-asserted-by":"publisher","first-page":"217105","DOI":"10.1016\/j.canlet.2024.217105","volume":"598","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. Inhibition of KIF20A enhances the immunotherapeutic effect of hepatocellular carcinoma by enhancing c-Myc ubiquitination. Cancer Lett. 598, 217105 (2024).","journal-title":"Cancer Lett."},{"key":"1060_CR23","doi-asserted-by":"publisher","first-page":"A001","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR18-A001","volume":"7","author":"Y Akazawa","year":"2019","unstructured":"Akazawa, Y. et al. Abstract A001: phase I study of vaccine therapy with a cocktail of peptides for pediatric patients with refractory solid tumors. Cancer Immunol. Res. 7, A001 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1060_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cytogfr.2023.06.006","volume":"71","author":"D Bandi","year":"2023","unstructured":"Bandi, D., Sarvesh, S., Farran, B., Nagaraju, G. & El-Rayes, B. Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions. Cytokine Growth F. R. 71, 26\u201339 (2023).","journal-title":"Cytokine Growth F. R."},{"key":"1060_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jhep.2019.03.007","volume":"71","author":"J Bayo","year":"2019","unstructured":"Bayo, J. et al. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets. J. Hepatol. 71, 78\u201390 (2019).","journal-title":"J. Hepatol."},{"key":"1060_CR26","doi-asserted-by":"publisher","first-page":"105896","DOI":"10.1016\/j.compbiomed.2022.105896","volume":"148","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. Identification of chromosomal instability-associated genes as hepatocellular carcinoma progression-related biomarkers to guide clinical diagnosis, prognosis and therapy. Comput. Biol. Med. 148, 105896 (2022).","journal-title":"Comput. Biol. Med."},{"key":"1060_CR27","doi-asserted-by":"publisher","first-page":"7267","DOI":"10.1021\/acsnano.3c13143","volume":"18","author":"Z Yang","year":"2024","unstructured":"Yang, Z. et al. Reinforced immunogenic endoplasmic reticulum stress and oxidative stress via an orchestrated nanophotoinducer to boost cancer photoimmunotherapy. ACS Nano 18, 7267\u20137286 (2024).","journal-title":"ACS Nano"},{"key":"1060_CR28","doi-asserted-by":"publisher","first-page":"e13622","DOI":"10.1111\/cpr.13622","volume":"57","author":"XTT Dang","year":"2024","unstructured":"Dang, X. T. T. et al. Dendritic cell-targeted delivery of antigens using extracellular vesicles for anti-cancer immunotherapy. Cell Prolif. 57, e13622 (2024).","journal-title":"Cell Prolif."},{"key":"1060_CR29","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1016\/j.apsb.2024.04.010","volume":"14","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Endoplasmic reticulum-targeted delivery of celastrol and PD-L1 siRNA for reinforcing immunogenic cell death and potentiating cancer immunotherapy. Acta Pharm. Sin. B 14, 3643\u20133660 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"1060_CR30","doi-asserted-by":"crossref","unstructured":"Raynor, J. L. & Chi, H. Nutrients: Signal 4 in T cell immunity. J. Exp. Med. 221 (2024).","DOI":"10.1084\/jem.20221839"},{"key":"1060_CR31","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1158\/1538-7445.AM2021-2719","volume":"81","author":"VC Kok","year":"2021","unstructured":"Kok, V. C., Wang, C. C. N., Liao, S.-H. & Chen, D.-L. Abstract 2719: Interleukin-17 and cytokine-related signalings are determinants for tumor immune microenvironment in triple-negative breast cancer: in silico integrated analysis. Cancer Res. 81, 2719\u20132719 (2021).","journal-title":"Cancer Res."},{"key":"1060_CR32","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41556-024-01462-3","volume":"26","author":"R-Y Shi","year":"2024","unstructured":"Shi, R.-Y. et al. Trafficking circuit of CD8+ T cells between the intestine and bone marrow governs antitumour immunity. Nat. Cell Biol. 26, 1346\u20131358 (2024).","journal-title":"Nat. Cell Biol."},{"key":"1060_CR33","doi-asserted-by":"publisher","first-page":"122569","DOI":"10.1016\/j.biomaterials.2024.122569","volume":"308","author":"Z Liang","year":"2024","unstructured":"Liang, Z. et al. The orientation of CpG conjugation on aluminum oxyhydroxide nanoparticles determines the immunostimulatory effects of combination adjuvants. Biomaterials 308, 122569 (2024).","journal-title":"Biomaterials"},{"key":"1060_CR34","doi-asserted-by":"crossref","unstructured":"Li, K. et al. A dual enhancing strategy of novel nanovaccine based on TIM3 silencing nanoadjuvants and desialylated cancer cell membrane antigens for personalized vaccination immunotherapy of cancer. Adv. Funct. Mater. 2404956 (2024).","DOI":"10.1002\/adfm.202404956"},{"key":"1060_CR35","doi-asserted-by":"publisher","first-page":"102365","DOI":"10.1016\/j.nantod.2024.102365","volume":"57","author":"J Schunke","year":"2024","unstructured":"Schunke, J. et al. Co-delivery of STING and TLR7\/8 agonists in antigen-based nanocapsules to dendritic cells enhances CD8+ T cell-mediated melanoma remission. Nano Today 57, 102365 (2024).","journal-title":"Nano Today"},{"key":"1060_CR36","doi-asserted-by":"crossref","unstructured":"Liu, X. et al. Mobilizing STING Pathway via a Cationic Liposome to Enhance Doxorubicin\u2010Induced Antitumor Immunity. Adv. Funct. Mater. 2416406 (2024).","DOI":"10.1002\/adfm.202416406"},{"key":"1060_CR37","doi-asserted-by":"publisher","first-page":"114198","DOI":"10.1016\/j.ejmech.2022.114198","volume":"233","author":"M Li","year":"2022","unstructured":"Li, M. et al. Cationic liposomes co-deliver chemotherapeutics and siRNA for the treatment of breast cancer. Eur. J. Med. Chem. 233, 114198 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"1060_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","volume":"17","author":"KY Shen","year":"2024","unstructured":"Shen, K. Y., Zhu, Y., Xie, S. Z. & Qin, L. X. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J. Hematol. Oncol. 17, 25 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"1060_CR39","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jconrel.2023.02.015","volume":"355","author":"Y Yi","year":"2023","unstructured":"Yi, Y. et al. Vaccine-like nanomedicine for cancer immunotherapy. J. Control. Release 355, 760\u2013778 (2023).","journal-title":"J. Control. Release"},{"key":"1060_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00943-8","volume":"9","author":"JF Hernandez-Franco","year":"2024","unstructured":"Hernandez-Franco, J. F., Jan, I. M., Elzey, B. D. & HogenEsch, H. Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity. npj Vaccines 9, 149 (2024).","journal-title":"npj Vaccines"},{"key":"1060_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00787-8","volume":"9","author":"D Jenika","year":"2024","unstructured":"Jenika, D. et al. In vivo assembly of epitope-coated biopolymer particles that induce anti-tumor responses. npj Vaccines 9, 18 (2024).","journal-title":"npj Vaccines"},{"key":"1060_CR42","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jconrel.2024.06.041","volume":"372","author":"PH Chao","year":"2024","unstructured":"Chao, P. H., Chan, V., Wu, J., Andrew, L. J. & Li, S. D. Resiquimod-loaded cationic liposomes cure mice with peritoneal carcinomatosis and induce specific anti-tumor immunity. J. Control. Release 372, 362\u2013371 (2024).","journal-title":"J. Control. Release"},{"key":"1060_CR43","doi-asserted-by":"publisher","first-page":"eabk3150","DOI":"10.1126\/sciadv.abk3150","volume":"8","author":"R Smith","year":"2022","unstructured":"Smith, R. et al. Cationic nanoparticles enhance T cell tumor infiltration and antitumor immune responses to a melanoma vaccine. Sci. Adv. 8, eabk3150 (2022).","journal-title":"Sci. Adv."},{"key":"1060_CR44","doi-asserted-by":"publisher","first-page":"115304","DOI":"10.1016\/j.addr.2024.115304","volume":"209","author":"Y Tang","year":"2024","unstructured":"Tang, Y. et al. Interactions between nanoparticles and lymphatic systems: mechanisms and applications in drug delivery. Adv. Drug Deliv. Rev. 209, 115304 (2024).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1060_CR45","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41573-024-00974-9","volume":"23","author":"N Gong","year":"2024","unstructured":"Gong, N. et al. Enhancing in situ cancer vaccines using delivery technologies. Nat. Rev. Drug Discov. 23, 607\u2013625 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1060_CR46","first-page":"315","volume":"31","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Intravesical chemotherapy synergize with an immune adjuvant by a thermo-sensitive hydrogel system for bladder cancer. Bioact. Mater. 31, 315\u2013332 (2024).","journal-title":"Bioact. Mater."},{"key":"1060_CR47","doi-asserted-by":"crossref","unstructured":"Guo, N. et al. Immunoinformatics design and in vivo immunogenicity evaluation of a conserved CTL multi-epitope vaccine targeting HPV16 E5, E6, and E7 proteins. Vaccines 12 (2024).","DOI":"10.3390\/vaccines12040392"},{"key":"1060_CR48","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jconrel.2018.10.008","volume":"292","author":"R Zhang","year":"2018","unstructured":"Zhang, R., Billingsley, M. M. & Mitchell, M. J. Biomaterials for vaccine-based cancer immunotherapy. J. Control. Release 292, 256\u2013276 (2018).","journal-title":"J. Control. Release"},{"key":"1060_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01363-y","volume":"16","author":"C Yang","year":"2024","unstructured":"Yang, C. et al. Identification of tumor rejection antigens and the immunologic landscape of medulloblastoma. Genome. Med. 16, 102 (2024).","journal-title":"Genome. Med."},{"key":"1060_CR50","doi-asserted-by":"crossref","unstructured":"Perez, M. A. S. et al. Predicting antigen-specificities of orphan T cell receptors from cancer patients with TCRpcDist. Adv. Sci., 2405949 (2024).","DOI":"10.1002\/advs.202405949"},{"key":"1060_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40207-y","volume":"14","author":"J Meng","year":"2023","unstructured":"Meng, J. et al. Generation of whole tumor cell vaccine for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation. Nat. Commun. 14, 4505 (2023).","journal-title":"Nat. Commun."},{"key":"1060_CR52","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","volume":"20","author":"J Chuprin","year":"2023","unstructured":"Chuprin, J. et al. Humanized mouse models for immuno-oncology research. Nat. Rev. Clin. Oncol. 20, 192\u2013206 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1060_CR53","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1158\/0008-5472.CAN-15-0727","volume":"75","author":"JW Cassidy","year":"2015","unstructured":"Cassidy, J. W., Caldas, C. & Bruna, A. Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Res. 75, 2963\u20132968 (2015).","journal-title":"Cancer Res."},{"key":"1060_CR54","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).","journal-title":"Innovation"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01060-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01060-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01060-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T07:16:54Z","timestamp":1735888614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01060-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-01060-2","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}